Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.
Dec 2020 | From Akero Therapeutics
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
Jul 2018 | FROM EXTERNAL EXPERTS
A systematic dissection of sequence elements determining β-Klotho and FGF interaction and signaling
![PSB-Image-Pipeline](https://akerotx.com/wp-content/uploads/2021/08/PSB-Image-Pipeline.jpg)
![PSB-Image-Pipeline](https://akerotx.com/wp-content/uploads/2021/08/PSB-Image-Pipeline.jpg)